ArticleNanoscale research letters2019
Graphene Oxide in a Composite with Silver Nanoparticles Reduces the Fibroblast and Endothelial Cell Cytotoxicity of an Antibacterial Nanoplatform.
Article in Nanoscale research letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Development and Evaluation of a Novel Self-Etch Dental Adhesive Incorporating Graphene Oxide-Zirconia (GO-ZrONanomaterials (Basel, Switzerland) · 2025Article
- The cytocompatibility of graphene oxide as a platform to enhance the effectiveness and safety of silver nanoparticles through in vitro studies.Environmental science and pollution research international · 2024Article
- Silver and Carbon Nanomaterials/Nanocomplexes as Safe and Effective ACE2-S Binding Blockers on Human Skin Cell Lines.Molecules (Basel, Switzerland) · 2024Article
- Article
- Study of Morphology Control of Electro-Deposited Silver on Electro-Chemically Exfoliated Graphene Electrode and Its Conductivity.Materials (Basel, Switzerland) · 2024Article
- Antimicrobial and Antibiofilm Potential of Green-Synthesized Graphene-Silver Nanocomposite against Multidrug-Resistant Nosocomial Pathogens.Biomedicines · 2024Article
- Effects of Temperature, Ionic Strength and Humic Acid on the Transport of Graphene Oxide Nanoparticles in Geosynthetic Clay Liner.Materials (Basel, Switzerland) · 2024Article
- Article
- Antitumoral melatonin-loaded nanostructured lipid carriers.Nanomedicine (London, England) · 2024Article
- Antiviral Activity of Graphene Oxide-Silver Nanocomposites Against Murine Betacoronavirus.International journal of nanomedicine · 2024Article
- Graphene-Based Composites for Biomedical Applications: Surface Modification for Enhanced Antimicrobial Activity and Biocompatibility.Biomolecules · 2023Review
- Silver Nanoparticles and Graphene Oxide Complex as an Anti-Inflammatory Biocompatible Liquid Nano-Dressing for Skin Infected withJournal of inflammation research · 2023Article
- An Update on Graphene Oxide: Applications and Toxicity.ACS omega · 2022Review
- Rational design of biodegradable thermoplastic polyurethanes for tissue repair.Bioactive materials · 2022Review
- Molecular Biocompatibility of a Silver Nanoparticle Complex with Graphene Oxide to Human Skin in a 3D Epidermis In Vitro Model.Pharmaceutics · 2022Article
- Nanocomposites of Graphene Oxide-Silver Nanoparticles for Enhanced Antibacterial Activity: Mechanism of Action and Medical Textiles Coating.Materials (Basel, Switzerland) · 2022Article
- Biological Effects, Applications and Design Strategies of Medical Polyurethanes Modified by Nanomaterials.International journal of nanomedicine · 2022Review
- Novel nanographene oxide-calcium phosphate cement inhibits Enterococcus faecalis biofilm and supports dental pulp stem cells.Journal of orthopaedic surgery and research · 2021Article
- Current approaches for the exploration of antimicrobial activities of nanoparticles.Science and technology of advanced materials · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
Antibacterial surfaces coated with nanomaterials, including silver nanoparticles, are considered effective alternative antimicrobial agents that can be used instead of antibiotics and chemical agents. However, reports of the potential toxicity of these materials raise questions about the safety of their use in biomedical applications. The objective of this research was to reduce the human cell cytotoxicity of silver nanoparticle-coated polyurethane foils by complexing silver nanoparticles with graphene oxide. The antimicrobial activity of nanoplatforms coated with silver nanoparticles, graphene oxide and the composite of silver nanoparticles and graphene oxide was assessed with Salmonella enteritidis. Cytotoxicity was analysed by an analysis of the viability and morphology of human fibroblasts, human umbilical vein endothelial cells (HUVECs) and chicken embryo chorioallantoic membrane. Additionally, the synthesis level of inflammatory proteins was examined for fibroblasts cultured on different nanoplatforms. The nanoplatform coated with the silver nanoparticles and graphene oxide composite showed strongest antibacterial properties, although nanoplatforms coated with only silver nanoparticles or graphene oxide also resulted in decreased S. enteritidis growth. Furthermore, a nanoplatform coated with silver nanoparticles and graphene oxide composite showed limited immunological stimulation and significantly reduced cytotoxicity towards fibroblasts, HUVECs and chicken embryo chorioallantoic membrane in comparison to the nanoplatform coated only with silver nanoparticles, due to the higher stability of the nanomaterials in the nanocomposite.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.